Addus HomeCare (ADUS)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- Home Healthsrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate as of 2026-10-06. ClinicalTrials.gov
Dilution Risk
LOW DILUTION RISKDilution score: 24/100 (LOW), cash runway not available
Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score
Short Interest
Short interest: 4.96% of float, squeeze risk: MODERATE
FINRA short sale data. FINRA short interest
Recent News & SEC Filings
- 2 Safe-and-Steady Stocks with Exciting Potential and 1 That Underwhelm
- Can Addus HomeCare (ADUS) Compound Wealth at Scale?
- Addus HomeCare (ADUS) Heads To Jefferies, Is It Still 13% Undervalued?
- Addus HomeCare's Acquisition of AccentCare's Personal Care Business Likely to Support Growth, UBS Says
- Sector Update: Healthcare Stocks Gain Late Afternoon
- Addus Advances M&A Strategy With Deal for AccentCare Personal Care Business
- Addus HomeCare Consolidation Can't Offset Medicaid Funding Pressures, BofA Says
- Addus HomeCare Announces a Definitive Agreement to Acquire Personal Care Division of AccentCare
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for Addus HomeCare.
Full ADUS Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.